Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Medtronic’s Valiant stent graft shows efficacy in new trial

Medtronic’s Valiant stent graft shows efficacy in new trial

21st June 2011

Medtronic has highlighted data from a new trial that demonstrates the high-quality clinical results provided by its Valiant thoracic stent graft system.

The medical device was recently utilised in a pivotal study called Valor II, in which it was trialled among 160 US patients requiring thoracic endovascular aortic repair of thoracic aortic aneurysms (TAA).

During the trial, the stent graft was able to meet all of its safety and efficacy endpoints, demonstrating a high rate of successful aneurysm treatments and a minimal rate of all-cause mortality.

It was noted that there were no cases of rupture or conversion to open surgery among the trial group, while very few stent grafts migrated from their original placement.

Lead investigator Dr Ronald Fairman of the University of Pennsylvania said: "The Valor II 12-month results demonstrate that the Medtronic Valiant stent graft is a safe and effective treatment for patients with descending TAA of degenerative etiology."

Last month, the firm showcased results from a study of its Resolute drug-eluting stent system, demonstrating the benefits it offers to heart disease and diabetes patients.ADNFCR-8000103-ID-800588940-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.